April 03, 2025

Oophorectomy May Elevate Heart Failure Risk

Bilateral ovary removal may increase heart failure risk 1.5-fold, with White women and younger patients facing double the risk, according to new research presented at ACC.25.

Conexiant

April 01, 2025

GEM Helps Put T2D in Remission

Researchers highlight evidence-based lifestyle and pharmacologic strategies, including glycemic excursion minimization and tirzepatide, for early glycemic control in adults with type 2 diabetes.

Conexiant

April 01, 2025

A Different Perspective on an Age-Old Disease

Discover how Optical Coherence Tomography (OCT) technology can revolutionize the management of posterior segment diseases in this engaging editorial content by Dr. James L. Fanelli.

Optometric Management

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

Coding Q&A: Coding Guidelines for Wet AMD

Ensure compliance and prompt payment by using proper ICD-10-CM codes for diagnosing patients with exudative age-related macular degeneration (wet AMD). Learn the guidelines for coding specific eye conditions and disease stages.

Retinal Physician

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Microplastics Linked to Cardiovascular Disease

Research reveals significant associations between environmental microplastic pollution and increased rates of hypertension, diabetes, and stroke across U.S. coastal communities, with pollution levels ranking among top predictors for chronic disease prevalence.

Conexiant

March 31, 2025

Clopidogrel Outshines Aspirin After PCI

“In our study, clopidogrel beat aspirin as a lifelong maintenance monotherapy after standard-duration dual antiplatelet therapy."

Conexiant

March 28, 2025

FDA Declines Cardamyst Approval Request

The FDA declined to approve Milestone’s etripamil nasal spray for PSVT, citing manufacturing issues and a need for more data on impurities, but raised no safety or efficacy concerns.

Reuters